Makoto Asada
Overview
Explore the profile of Makoto Asada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribeiro I, Blum B, Fernandes J, Santina G, Asada M, Everson M, et al.
Antimicrob Agents Chemother
. 2021 Feb;
65(4).
PMID: 33558286
E1224 is a prodrug of ravuconazole (RVZ), an antifungal drug with promising anti- activity, the causative organism of Chagas disease (CD). This study was designed to assess the pharmacokinetics (PK)...
2.
3.
Asada M
Yakugaku Zasshi
. 2016 Feb;
136(2):223-30.
PMID: 26831797
The Pharmaceutical Industry is expected to play a proactive global role in combatting neglected tropical diseases (NTDs) and other tropical diseases affecting low-income countries. Such a role would include novel...
4.
Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al.
Vasc Cell
. 2014 Sep;
6:18.
PMID: 25197551
Background: Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor α (PDGFR...
5.
Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y
Cancer Sci
. 2014 May;
105(8):1023-31.
PMID: 24841832
Most non-small-cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, they invariably develop resistance to...
6.
Ozawa Y, Kusano K, Owa T, Yokoi A, Asada M, Yoshimatsu K
Cancer Chemother Pharmacol
. 2012 Feb;
69(5):1353-62.
PMID: 22349812
Purpose: Indisulam (N-(-3-chloro-7-indolyl)-1,4-benzenedisulfonamide; E7070) is an experimental anticancer agent. Microarray analysis indicates that indisulam downregulates several genes involved in drug resistance, and this finding led us to test the effect...
7.
Miyazaki M, Horii T, Hata K, Watanabe N, Nakamoto K, Tanaka K, et al.
Antimicrob Agents Chemother
. 2011 Aug;
55(10):4652-8.
PMID: 21825291
E1210 is a new antifungal compound with a novel mechanism of action and broad spectrum of antifungal activity. We investigated the in vitro antifungal activities of E1210 compared to those...
8.
Hata K, Horii T, Miyazaki M, Watanabe N, Okubo M, Sonoda J, et al.
Antimicrob Agents Chemother
. 2011 Jul;
55(10):4543-51.
PMID: 21788462
E1210 is a first-in-class, broad-spectrum antifungal with a novel mechanism of action-inhibition of fungal glycosylphosphatidylinositol biosynthesis. In this study, the efficacies of E1210 and reference antifungals were evaluated in murine...
9.
Nakamoto K, Tsukada I, Tanaka K, Matsukura M, Haneda T, Inoue S, et al.
Bioorg Med Chem Lett
. 2010 Jun;
20(15):4624-6.
PMID: 20573507
Quinoline amide, azaindole amide and pyridine amides were synthesized and tested for in vitro antifungal activity against fungi. These synthesized amides have potent antifungal activity against Candida albicans and Aspergillus...
10.
Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, et al.
Cancer Sci
. 2009 Oct;
101(1):210-5.
PMID: 19832844
c-Met is the cellular receptor for hepatocyte growth factor (HGF) and is known to be dysregulated in various types of human cancers. Activation of the HGF/c-Met pathway causes tumor progression,...